Journal of International Oncology››2022,Vol. 49››Issue (9): 568-571.doi:10.3760/cma.j.cn371439-20220511-00111
• Reviews •Previous ArticlesNext Articles
Shi Yingxia1, Hu Lijun2, Yu Jingping3(
)
Received:2022-05-11Revised:2022-05-24Online:2022-09-08Published:2022-10-21Contact:Yu Jingping E-mail:yujingping700420@sina.comSupported by:
Shi Yingxia, Hu Lijun, Yu Jingping. Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 568-571.
| [1] | Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities[J]. J Natl Med Assoc, 2020, 112(2): 229-232. DOI: 10.1016/j.jnma.2020.03.002. doi:S0027-9684(20)30043-2pmid:32278478 |
| [2] | Liontos M, Kyriazoglou A, Dimitriadis I, et al. Systemic therapy in cervical cancer: 30 years in review[J]. Crit Rev Oncol Hematol, 2019, 137: 9-17. DOI: 10.1016/j.critrevonc.2019.02.009. doi:S1040-8428(18)30340-8pmid:31014518 |
| [3] | Wendel Naumann R, Leath CA 3rd. Advances in immunotherapy for cervical cancer[J]. Curr Opin Oncol, 2020, 32(5): 481-487. DOI: 10.1097/CCO.0000000000000663. doi:10.1097/CCO.0000000000000663pmid:32740092 |
| [4] | Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ⅰb KEYNOTE-028 trial[J]. J Clin Oncol, 2017, 35(36): 4035-4041. DOI: 10.1200/JCO.2017.74.5471. doi:10.1200/JCO.2017.74.5471 |
| [5] | Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478. DOI: 10.1200/JCO.18.01265. doi:10.1200/JCO.18.01265 |
| [6] | Cohen AC, Roane BM, Leath CA. Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy[J]. Drugs, 2020, 80(3): 217-227. DOI: 10.1007/s40265-019-01249-z. doi:10.1007/s40265-019-01249-zpmid:31939072 |
| [7] | Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867. DOI: 10.1056/NEJMoa2112435. doi:10.1056/NEJMoa2112435 |
| [8] | 中华医学会妇科肿瘤学分会. 妇科肿瘤免疫检查点抑制剂临床应用指南[J]. 协和医学杂志, 2021, 12(6): 854-880. DOI: 10.12290/xhyxzz.2021-0683. doi:10.12290/xhyxzz.2021-0683 |
| [9] | Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durva-lumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018, 379(24): 2342-2350. DOI: 10.1056/NEJMoa1809697. doi:10.1056/NEJMoa1809697 |
| [10] | Lin AJ, Dehdashti F, Massad LS, et al. Long-term outcomes of cervical cancer patients treated with definitive chemoradiation following a complete metabolic response[J]. Clin Oncol (R Coll Radiol), 2021, 33(5): 300-306. DOI: 10.1016/j.clon.2021.01.010. doi:10.1016/j.clon.2021.01.010pmid:33581976 |
| [11] | Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase Ⅰ/Ⅱ CheckMate 358 trial[J]. J Clin Oncol, 2019, 37(31): 2825-2834. DOI: 10.1200/JCO.19.00739. doi:10.1200/JCO.19.00739pmid:31487218 |
| [12] | Da Silva DM, Enserro DM, Mayadev JS, et al. Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)[J]. Clin Cancer Res, 2020, 26(21): 5621-5630. DOI: 10.1158/1078-0432.CCR-20-0776. doi:10.1158/1078-0432.CCR-20-0776 |
| [13] | Lheureux S, Butler MO, Clarke B, et al. Association of ipili-mumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma[J]. JAMA Oncol, 2018, 4(7): e173776. DOI: 10.1001/jamaoncol.2017.3776. doi:10.1001/jamaoncol.2017.3776 |
| [14] | Anipindi M, Smith RJ, Gilani M. Case report: immune checkpoint inhibitors as a single agent in the treatment of metastatic cervical cancer[J]. Front Oncol, 2022, 12: 856944. DOI: 10.3389/fonc.2022.856944. doi:10.3389/fonc.2022.856944 |
| [15] | O'Malley DM, Randall LM, Jackson CG, et al. RaPiDS (GOG-3028): randomized Phase Ⅱ study of balstilimab alone or in combination with zalifrelimab in cervical cancer[J]. Future Oncol, 2021, 17(26): 3433-3443. DOI: 10.2217/fon-2021-0529. doi:10.2217/fon-2021-0529pmid:34409858 |
| [16] | Feng CH, Mell LK, Sharabi AB, et al. Immunotherapy with radio-therapy and chemoradiotherapy for cervical cancer[J]. Semin Radiat Oncol, 2020, 30(4): 273-280. DOI: 10.1016/j.semradonc.2020.05.003. doi:10.1016/j.semradonc.2020.05.003 |
| [17] | Dyer BA, Feng CH, Eskander R, et al. Current status of clinical trials for cervical and uterine cancer using immunotherapy combined with radiation[J]. Int J Radiat Oncol Biol Phys, 2021, 109(2): 396-412. DOI: 10.1016/j.ijrobp.2020.09.016. doi:10.1016/j.ijrobp.2020.09.016 |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
